Inventiva (NASDAQ:IVA) Shares Gap Down – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares gapped down before the market opened on Wednesday . The stock had previously closed at $3.97, but opened at $3.74. Inventiva shares last traded at $3.8510, with a volume of 95,913 shares.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wall Street Zen cut shares of Inventiva from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Truist Financial began coverage on shares of Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Inventiva in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $16.56.

Inventiva Trading Down 4.7%

The firm’s 50-day moving average price is $5.17 and its two-hundred day moving average price is $5.40.

Inventiva (NASDAQ:IVA) last posted its earnings results on Sunday, February 15th. The company reported ($0.16) EPS for the quarter. The business had revenue of $0.01 million for the quarter. Analysts expect that Inventiva S.A. Sponsored ADR will post -0.8 earnings per share for the current year.

Institutional Trading of Inventiva

A number of large investors have recently made changes to their positions in IVA. Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 55.6% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock valued at $142,000 after purchasing an additional 9,212 shares during the last quarter. Creative Planning purchased a new position in Inventiva in the second quarter valued at approximately $32,000. Commonwealth Equity Services LLC increased its stake in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock valued at $361,000 after purchasing an additional 12,704 shares during the last quarter. Virtu Financial LLC purchased a new position in Inventiva in the fourth quarter valued at approximately $60,000. Finally, XTX Topco Ltd purchased a new position in Inventiva in the fourth quarter valued at approximately $84,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.